IN THE CLAIMS

Please amend the claims as follows:

Claims 1-6 (Cancelled)

Claim 7 (Currently Amended): A method for identifying a gamma-secretase and/or a beta-secretase modulator, comprising ~~the following steps~~:

a) ~~identifying of~~ contacting a molecule with LAPTM4B (lysosomal associated transmembrane protein 4 beta protein) that has at least 90% identity with the amino acid of SEQ ID NO: 1 ~~interacting molecule by determining whether a given test compound is a LAPTM4B-interacting molecule~~, and

b) determining whether ~~the LAPTM4B-interacting~~ said molecule ~~of step a) is capable of modulating~~ increases or decreases gamma-secretase and/or beta-secretase activity,

thereby identifying a molecule that modulates gamma-secretase and/or a beta-secretase;

wherein said LAPTM4B has at least 90% identity with the amino acid sequence of SEQ ID NO: 1.

Claim 8 (Currently Amended): The method of claim 7, wherein the ability of said molecule to decrease gamma- or beta-secretase activity is determined ~~in step a) the test compound is brought into contact with LAPTM4B and the interaction of LAPTM4B with the test compound is determined~~.

Claim 9 (Currently Amended): The method of claim 8, wherein the ability of said molecule to increase gamma- or beta-secretase activity is determined ~~the interaction of the test compound with LAPTM4B results in an inhibition of LAPTM4B activity~~.

Claim 10 (Currently Amended): The method of <u>claim 7</u> ~~any of claims 7 to 9~~, wherein ~~in step b) the ability of the~~ gamma-secretase and/or the beta-secrease <u>activity is determined</u> <u>by measuring their ability</u> to cleave APP <u>(amyloid precursor protein)</u> ~~is measured, preferably~~ ~~wherein the ability to produce Abeta 42 is measured~~.

Claim 11 (Withdrawn, Currently Amended): A method for preparing a pharmaceutical composition for the treatment of <u>a</u> neurodegenerative disease[[s]], comprising ~~the following steps~~:

a) identifying a gamma-secretase and/or beta-secretase modulator <u>by the method of</u> <u>claim 7</u> ~~according to claims 7 to 10~~, and

b) formulating the gamma-secretase and/or beta-secretase modulator <u>into</u> a pharmaceutical composition.

Claim 12 (Withdrawn, Currently Amended): The method of claim 11, further comprising ~~the step of~~ mixing ~~the identified molecule~~ <u>said gamma- and/or beta-secretase</u> with a pharmaceutically acceptable carrier.

Claim 13 (Withdrawn, Currently Amended): A pharmaceutical composition comprising a LAPTM4B-inhibitor ~~as defined in any of claims 1 to 5~~ <u>obtained by the method</u> <u>of Claim 7</u>.

Claim 14 (Withdrawn, Currently Amended): A pharmaceutical composition obtainable by the method according to <u>claim 11</u> ~~any of claims 11 or 12~~.

Claim 15 (Withdrawn, Currently Amended): The pharmaceutical composition according to ~~any of claims 13 or 14~~ for the treatment of neurodegenerative disease such as Alzheimer's disease and related neurodegenerative disorders.

Claim 16 (Withdrawn, Currently Amended) A method for treating ~~or preventing~~ a neurodegenerative disease~~, preferably Alzheimer's disease administering to a subject in need of such treatment or prevention~~ comprising administering a therapeutically effective amount of a pharmaceutical composition of <u>claim 13 to a subject in need thereof</u> ~~any of claims 13 to 15~~.

Claim 17 (Cancelled)

Claim 18 (New): The method of claim 7, wherein said LAPTM4B molecule is at least 95% identical to the amino acid sequence of SEQ ID NO: 1.

Claim 19 (New): The method of claim 7, wherein said LAPTM4B molecule is at least 99% identical to the amino acid sequence of SEQ ID NO: 1.

Claim 20 (New): The method of claim 10, comprising measuring the production of Abeta-42 or $A\beta1$-42.